Previous editions of EJC News Focus
- November 2011
Gordon Mills assesses the challenges we face in developing personalised medicine.
- October 2011
Richard Sullivan explains why the spiralling rise in healthcare costs associated with cancer is unsustainable.
- September 2011
Anne-Lise Borresen-Dale discusses key themes to emerge at the European Multidisciplinary Cancer Congress in Stockholm.
- August 2011
Jean-Charles Soria, EJC's Drug Development Editor, on the need for a new consensus on assessing toxicities.
- July 2011
EJC editor-in-chief Alexander Eggermont on recent advances in melanoma treatment.
- June 2011
Jean-Yves Blay discusses how EORTC is adapting to the new environment for research.
- April/May 2011
Cora Sternberg reveals exciting developments in the treatment of prostate cancer.
- March 2011
EJC's editor for gastrointestinal cancers, Eric van Cutsem, discusses the disappointing findings of recent trials of bevacizumab in colon cancer
- February 2011
Michel Coleman from the London School of Hygiene and Tropical Medicine discusses a comparison of cancer survival rates in different countries.
- January 2011
Jan Willem Coebergh discusses a paper relating to the NELSON lung cancer trial.
EJC News Focus – October 2011
Healthcare costs associated with cancer are spiralling out of control in developed countries, say the authors of a Commission published by The Lancet Oncology (2011; 12:933-80).
Ageing populations are a key factor; age is the single biggest risk factor for cancer and by 2040, between 25 and 32% of the developed world will be aged 65 years or older. Increasingly expensive technological innovations are becoming available, and, further, this is all set against the background of a shift in cultural attitudes. Demand from the general public for these high end expensive therapies is rising, along with increasing political willingness to deliver.
The Commission was launched at the 2011 European Multidisciplinary Cancer Congress in Stockholm and in this month’s EJC News Focus, lead author Richard Sullivan (King’s College Integrated Cancer Centre, London UK) explains why the situation is unsustainable.